LSP POLAR

Relapsed/refractory MM phase 3 trial comparing carfilzomib with dex vs carfilzomib with mezigdomide (Cel Mod) with dex. Please let me know if you have any patients who are refractory to Imid and anti CD38 therapy.
Status:

Open

Trial Type:

Contact:

Rabin Niroula, MD
rabin.niroula@brownhealth.org